Open-label extension of a randomized, double-blind, placebo- and active-controlled, parallel-group, dose-response study to evaluate the efficacy and safety of 2 fixed dosages of extended release OROS paliperidone (6 and 12 mg/day) and olanzapine (10 mg/day), in patients with schizophrenia

Trial Profile

Open-label extension of a randomized, double-blind, placebo- and active-controlled, parallel-group, dose-response study to evaluate the efficacy and safety of 2 fixed dosages of extended release OROS paliperidone (6 and 12 mg/day) and olanzapine (10 mg/day), in patients with schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2010

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Apr 2010 Actual end date added to 1 Dec 2005 as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Actual patient number (203) added as reported by ClinicalTrials.gov.
    • 11 Oct 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top